非小细胞肺癌患者血清HMGB2和HMGB3水平及临床意义  

Levels of serum HMGB2 and HMGB3 and clinical significance in non-small cell lung cancer patients

作　　者：刘昊[1] 靳二梅 丁红娟 金磊[1] Liu Hao;Jin Ermei;Ding Hongjuan;Jin Lei(Department of Cardiothoracic Surgery,First Affiliated Hospital of Xi'an Medical University,Xi'an 710000,China)

机构地区：[1]西安医学院第一附属医院心胸外科,西安710000

出　　处：《国际肿瘤学杂志》2024年第7期448-452,共5页Journal of International Oncology

摘　　要：目的探究非小细胞肺癌(NSCLC)患者的血清高迁移率族蛋白(HMGB)2和HMGB3水平及临床意义。方法选取2020年1月—2022年1月西安医学院第一附属医院收治的137例NSCLC患者作为NSCLC组,另选取同期健康体检者90例作为健康组,比较两组血清HMGB2、HMGB3水平,分析血清HMGB2、HMGB3水平与NSCLC患者临床病理特征的关系;根据NSCLC患者预后情况分为预后良好组(n=86)和预后不良组(n=51),并比较两组的临床资料;采用多因素logistic回归分析NSCLC患者预后的影响因素;采用受试者操作特征(ROC)曲线分析血清HMGB2、HMGB3对NSCLC患者预后的预测价值。结果NSCLC组的血清HMGB2[(6.35±1.66)ng/ml比(2.58±0.76)ng/ml,t=20.19,P<0.001]、HMGB3[(2.48±0.56)ng/ml比(1.09±0.13)ng/ml,t=23.13,P<0.001]水平均高于健康组。有吸烟史(t=2.80,P=0.006;t=5.04,P<0.001)、有淋巴结转移(t=3.53,P=0.001;t=4.02,P<0.001)、TNM分期为Ⅲ~Ⅳ期(t=2.58,P=0.011;t=3.82,P<0.001)的NSCLC患者血清HMGB2、HMGB3水平均显著高于无吸烟史、无淋巴结转移、TNM分期为Ⅰ~Ⅱ期的患者。预后不良组患者的血清HMGB2[(7.80±1.83)ng/ml比(5.49±1.56)ng/ml,t=7.85,P<0.001]、HMGB3[(2.91±0.78)ng/ml比(2.23±0.43)ng/ml,t=6.58,P<0.001]水平均高于预后良好组,有淋巴结转移(χ^(2)=4.81,P=0.028)、有吸烟史(χ^(2)=11.67,P=0.001)、TNM分期的Ⅲ~Ⅳ期(χ^(2)=6.18,P=0.013)患者占比均显著高于预后良好组。多因素logistic回归分析结果显示,淋巴结转移(OR=1.96,95%CI为1.14~3.36,P=0.015)、吸烟史(OR=2.02,95%CI为1.33~3.06,P=0.001)、TNM分期(OR=2.28,95%CI为1.35~3.86,P=0.002)、HMGB2(OR=2.01,95%CI为1.40~2.91,P<0.001)、HMGB3(OR=1.99,95%CI为1.25~3.15,P=0.003)水平均为NSCLC患者预后的独立影响因素。ROC曲线分析显示,血清HMGB2、HMGB3单独和联合预测NSCLC患者预后情况的曲线下面积(AUC)分别为0.833、0.862、0.922,二者联合预测的AUC显著高于血清HMGB2(Z=2.44,P=0.015)、HMGB3(Z=2.54,P=0.011)单独预测。结论NSCLC患者�Objective To investigate the levels of serum high mobility group box(HMGB)2 and HMGB3 and clinical significance in patients with non-small cell lung cancer(NSCLC).Methods A total of 137 NSCLC patients admitted to the First Affiliated Hospital of Xi'an Medical University from January 2020 to January 2022 were selected as the NSCLC group,and another 90 cases who underwent healthy medical checkups during the same period were selected as the healthy group.Serum HMGB2 and HMGB3 levels were compared between the two groups.The relationship between serum HMGB2 and HMGB3 levels and the clinical and pathological characteristics of NSCLC patients was analyzed.NSCLC patients were divided into a good prognosis group(n=86)and a poor prognosis group(n=51)according to the prognosis,and the clinical data of the two groups were compared.Multivariate logistic regression was used to analyze the influencing factors of the prognosis of NSCLC patients.Receiver operator characteristic(ROC)curve was used to analyze the predictive value of serum HMGB2 and HMGB3 on the prognosis of NSCLC patients.Results Serum HMGB2[(6.35±1.66)ng/ml vs.(2.58±0.76)ng/ml,t=20.19,P<0.001]and HMGB3[(2.48±0.56)ng/ml vs.(1.09±0.13)ng/ml,t=23.13,P<0.001]levels in NSCLC group were higher than those in healthy group.Serum HMGB2 and HMGB3 levels of NSCLC patients with a history of smoking(t=2.80,P=0.006;t=5.04,P<0.001),lymph node metastasis(t=3.53,P=0.001;t=4.02,P<0.001),and TNM stageⅢ-Ⅳ(t=2.58,P=0.011;t=3.82,P<0.001)were significantly higher than those of patients with no history of smoking,no lymph node metastasis,and TNM stageⅠ-Ⅱ.The serum levels of HMGB2[(7.80±1.83)ng/ml vs.(5.49±1.56)ng/ml,t=7.85,P<0.001]and HMGB3[(2.91±0.78)ng/ml vs.(2.23±0.43)ng/ml,t=6.58,P<0.001]in the poor prognosis group were higher than those in the good prognosis group,and the proportion of patients with lymph node metastasis(χ^(2)=4.81,P=0.028),history of smoking(χ^(2)=11.67,P=0.001),and TNM stageⅢ-Ⅳ(χ^(2)=6.18,P=0.013)was significantly higher than that in the goo

关 键 词：癌 非小细胞肺 HMGB2蛋白质 HMGB3蛋白质 

分 类 号：R734.2[医药卫生—肿瘤]